Please use this identifier to cite or link to this item:
Title: Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity
Authors: Pingaew R.
Mandi P.
Nantasenamat C.
Prachayasittikul S.
Ruchirawat S.
Prachayasittikul V.
Keywords: acetophenone
benzoic acid
triazole derivative
unclassified drug
antineoplastic agent
isoquinoline derivative
triazole derivative
animal cell
antineoplastic activity
antiproliferative activity
cancer cell line
click chemistry
controlled study
drug design
drug structure
drug synthesis
HepG2 cell line
IC 50
molecular docking
Pictet Spengler reaction
substitution reaction
cell proliferation
chemical structure
Chlorocebus aethiops
dose response
drug design
drug effects
drug screening
structure activity relation
tumor cell line
Vero cell line
Antineoplastic Agents
Cell Line, Tumor
Cell Proliferation
Cercopithecus aethiops
Dose-Response Relationship, Drug
Drug Design
Drug Screening Assays, Antitumor
Hep G2 Cells
Molecular Docking Simulation
Molecular Structure
Structure-Activity Relationship
Vero Cells
Issue Date: 2014
Abstract: A novel series of N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinolines (14-33) containing triazole moiety were designed and synthesized through rational cycloadditions using the modified Pictet-Spengler reaction and the Click chemistry. Antiproliferative activity against four cancer cell lines (e.g., HuCCA-1, HepG2, A549 and MOLT-3) revealed that many substituted triazole analogs of benzoates (20, 29) and benzaldehydes (30, 32) exhibited anticancer activity against all of the tested cancer cell lines in which the ester analog 20 was shown to be the most potent compound against HuCCA-1 (IC50 = 0.63 μM) and A549 (IC50 = 0.57 μM) cell lines. Triazoles bearing phenyl (15, 24), tolyl (26, 27), acetophenone (19), benzoate (20, 29), benzaldehyde (21, 30) and naphthalenyl (25) substituents showed stronger anticancer activity against HepG2 cells than that of the etoposide. Interestingly, the p-tolyl analog (27) displayed the most potent inhibitory activity (IC50 = 0.56 μM) against HepG2 cells without affecting normal cells. Of the investigated tetrahydroisoquinoline-triazoles, the promising compounds 20 and 27 were selected for molecular docking against AKR1C3, which was identified to be a plausible target site. © 2014 Elsevier Masson SAS. All rights reserved.
ISSN: 2235234
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.